Introduction
============

Patients with gastric cancer may have poor health-related quality of life (QoL) resulting from the disease itself before surgery. Patients may still suffer from poor QoL due to the consequences of surgery after a gastrectomy. The overall survival rate of patients with gastric cancer has increased due to the development of diagnostic tools, mass screening programs, and advancements in multimodality management. However, significant morbidity, including early satiety, loss of appetite, heartburn, dysphagia, nausea, and vomiting is still associated with gastrectomy. These symptoms have a profound impact on QoL of postoperative patients. As a result, health providers and researchers have increasingly focused on improving life satisfaction of survivors \[[@b1-crt-2015-398]\].

QoL is a multi-dimensional construct covering several key dimensions including disease and treatment-related symptoms as well as physical, psychological, and social functioning. The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 is a reliable and validated measure of the QoL of patients with cancer in international trials in oncology \[[@b2-crt-2015-398]\]. The Korean version of this questionnaire has also been validated \[[@b3-crt-2015-398]\]. The questionnaire is a cancer-specific, self-administered, structured questionnaire including 30 questions composed of both multi-item scales and single-item measures. These scales/items include five functional scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/QoL scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). These 15 scales/items are grouped as follows: a global health status/QoL scale, five functional scales, and nine symptom scales/items.

The gastric cancer module (QLQ-STO22) is a supplement to the QLQ-C30 \[[@b4-crt-2015-398]\]. The QLQ-STO22 consists of 22 questions evaluating five multi-item symptoms scales (dysphagia, pain, reflux symptoms, eating restrictions, and anxiety), and four single items (dry mouth, taste, body image, and hair loss).

QoL has become an increasingly important factor for long-term survivors after surgery for gastric cancer. Several studies have examined QoL after a gastrectomy in patients with gastric cancer using EORTC QLQ-C30 and QLQ-STO22. A few studies have prospectively evaluated changes in QoL after surgery in short-term survivors \[[@b5-crt-2015-398]-[@b9-crt-2015-398]\]. However, most studies have important limitations, including, above all, small sample size \[[@b10-crt-2015-398]-[@b12-crt-2015-398]\] and retrospective study design \[[@b13-crt-2015-398],[@b14-crt-2015-398]\].

Researchers attempted to determine the relationship between postoperative QoL and the extent of gastric resection \[[@b9-crt-2015-398],[@b13-crt-2015-398]\], type of reconstruction after gastrectomy \[[@b15-crt-2015-398]\], and method of abdominal approach \[[@b8-crt-2015-398],[@b16-crt-2015-398]\], reaching varied conclusions \[[@b5-crt-2015-398]\]. As QoL changes over time, good knowledge regarding long-term chronological changes in QoL of relapse-free patients after a gastrectomy is essential to providing more appropriate care for patients. However, no study has prospectively evaluated the longitudinal changes in QoL of long-term survivors.

In this study, we prospectively evaluated the chronological changes in QoL after a gastrectomy over a 5-year postoperative period in a large group of patients.

Materials and Methods
=====================

1. Patients
-----------

A total of 1,105 patients who underwent a curative gastrectomy for primary gastric cancer between January 2008 and June 2010 at the Kyungpook National University Hospital were enrolled in this prospective cohort study. Among them, 439 patients completed the entire series of QoL assessments during the 5-year postoperative period; 161 patients with co-morbidities that could affect the QoL including cardiovascular disease, diabetes mellitus, chronic respiratory disease, chronic hepatic disease, and cerebrovascular disease and 24 patients who underwent another operation were excluded. The QoL data obtained from the remaining 254 patients were analyzed. The study was approved by the Institutional Review Board of Kyungpook National University Hospital (No. 201510035001).

The demographic characteristics of the patients are shown in [Table 1](#t1-crt-2015-398){ref-type="table"}. There were 95 female and 159 male patients. The mean age was 54.9±10.7 years. Most patients had stage I disease. Subtotal gastrectomy was performed on 202 patients and 52 patients underwent a total gastrectomy. Patients showed no evidence of recurrence at the final follow-up visit.

2. QoL assessment
-----------------

QoL was assessed using the Korean Versions of the EORTC QLQ-C30 and QLQ-STO22. All patients were asked to complete the questionnaires by themselves on the day of admission and at regular follow-up visits (1, 2, 3, 4, and 5 years after surgery). The raw scores were transformed to scores ranging from 0 to 100 according to the scoring manual provided by the EORTC \[[@b17-crt-2015-398]\]. A high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems. For the EORTC QLQ-STO22, a high score represents a low QoL.

3. Statistical analyses
-----------------------

The mean scores of each scale were compared in a longitudinal fashion across five postoperative years. One way analysis of variance followed by a Bonferroni *post-hoc* test or Dunnett T3 *post-hoc* test was performed for comparison of differences in the mean scores among the time intervals. p-values of less than 0.05 were considered statistically significant.

Results
=======

Preoperative and 5-year postoperative mean scores of EORTC QLQ-C30 and QLQ-STO22 scales/items are shown in [Table 2](#t2-crt-2015-398){ref-type="table"}.

Global health status/QoL tended to increase after the first postoperative year and the mean score at the 5th postoperative year was significantly higher than 1 year after the gastrectomy (p=0.012) ([Fig. 1](#f1-crt-2015-398){ref-type="fig"}). Physical functioning score, role functioning score, and cognitive functioning score decreased significantly in the first postoperative year (p \< 0.001, p \< 0.001, and p=0.001, respectively), but showed no significant changes thereafter. Emotional functioning was worst at baseline and improved steadily after surgery. Social functioning scores showed no statistically significant changes compared to preoperative score during the 5-year postoperative period ([Fig. 2](#f2-crt-2015-398){ref-type="fig"}).

Fatigue score increased significantly 1 year after surgery (p \< 0.001) and then decreased gradually. However, scores remained high during the 5 years postoperatively (p=0.045). Nausea and vomiting score and pain score increased 1 year after surgery without significance and tended to decrease afterward ([Fig. 3](#f3-crt-2015-398){ref-type="fig"}).

There were no statistically significant changes in dyspnea, insomnia, appetite loss, and constipation scores compared with preoperative scores during the 5-year postoperative period. Financial difficulties showed a similar pattern. Diarrhea score increased significantly 1 year after surgery (p \< 0.001). Although there was a tendency to decrease afterward, diarrhea score was significantly higher 5 years after surgery compared with the preoperative level ([Fig. 4](#f4-crt-2015-398){ref-type="fig"}).

The changes in the mean scores of QLQ-STO22 scales/items are shown in [Figs. 5](#f5-crt-2015-398){ref-type="fig"} and [6](#f6-crt-2015-398){ref-type="fig"}. Dysphagia and eating restrictions showed significant worsening 1 year after surgery (p \< 0.001 and p \< 0.001, respectively). Despite gradual improvements in these symptoms, the scores showed significantly higher levels compared with preoperative levels 5 years after the gastrectomy (p \< 0.001 and p \< 0.001, respectively). Reflux symptoms persisted during the 5-year postoperative period without significant changes. Anxiety had increased significantly 1 year after surgery (p \< 0.001), then decreased gradually. The difference showed no statistical significance 3 years after a gastrectomy. Although taste score showed significant worsening 1 year after surgery (p=0.008), there were no significant differences after 2 years postoperatively. Worsened body image had not recovered at 5 years after the gastrectomy. No significant changes were observed for pain, dry mouth, and hair loss.

Discussion
==========

Similar to another study \[[@b5-crt-2015-398]\], our results showed that the global health status/QoL decreased slightly during the first postoperative year and tended to increase afterward. Social functioning, nausea and vomiting, and pain showed a similar pattern. There were no statistically significant changes in the dyspnea, insomnia, appetite loss, constipation, financial difficulties, dry mouth, and hair loss scores compared with preoperative scores during the 5-year postoperative period. Hair loss is often used for assessment of QoL related to chemotherapy or radiotherapy for various types of cancer. Former cancer patients appear to pay less attention to their hair as long as they remain free of disease following cancer surgery. Similar to other studies \[[@b7-crt-2015-398],[@b11-crt-2015-398],[@b12-crt-2015-398]\], emotional functioning was the worst at baseline and showed constant improvement after surgery. Emotional functioning appears to be related to the depression caused by the initial diagnosis of cancer, and patients were gradually relieved from depression regarding their disease over time. Anxiety score also reached preoperative level 5 years after the gastrectomy.

A gastrectomy has a temporary negative impact on most aspects of QoL, and recovery typically occurs within the six or 12 postoperative months \[[@b5-crt-2015-398],[@b10-crt-2015-398]\]. However, some aspects of impaired QoL persist for a long period. The QoL of long-term survivors after a gastrectomy is influenced by the surgery itself as well as past memories of malignancy even when patients are considered to be disease-free \[[@b18-crt-2015-398]\].

Kong et al. \[[@b7-crt-2015-398]\] reported that physical functioning and role functioning showed the lowest scores after surgery and did not fully recover to preoperative levels until 1 year after surgery. In addition, scores for fatigue, nausea and vomiting, diarrhea, dysphagia, eating restriction, anxiety, taste, and body image remained significantly higher 1 year after surgery. Therefore, the authors recommended further follow-up to confirm whether these scales/items will recover or not. Among them, our study showed that scores for nausea and vomiting, anxiety, and taste gradually returned to the preoperative levels and showed no significant differences 5 years after a gastrectomy. However, changed physical functioning, role functioning, fatigue, diarrhea, dysphagia, eating restrictions, and body image did not recover even 5 years after a gastrectomy.

Cancer and its treatments are associated with increased fatigue that may persist for years after cancer eradication \[[@b19-crt-2015-398]\]. Our results showed that fatigue score was the highest 1 year after the gastrectomy and remained at a significantly increased level until 5 years after surgery.

Although there was no statistically significant change in global health status/QoL, our study found low QoL related to upper gastrointestinal symptoms including diarrhea, dysphagia, reflux symptoms, and eating restrictions in long-term survivors. Decreased physical functioning, role functioning, and cognitive functioning, fatigue, and a poor body image also impact QoL for a long time.

While surviving 5 years after surgery is often regarded as a turning point in the fight against cancer, in terms of QoL, survivors after a gastrectomy still have persistent needs for management of QoL \[[@b18-crt-2015-398],[@b20-crt-2015-398]\]. Management of symptoms should be specifically targeted as part of patient care after a gastrectomy. Development of appropriate interventions and individual management for each symptom by surgeons is required for patients with these symptoms.

The ultimate goal of the QoL assessment of cancer patients is to restore them to a healthy period as rapidly as possible \[[@b18-crt-2015-398]\]. Although physical functioning, role functioning, cognitive functioning, and body image may deteriorate with age, proper nutritional care including monitoring and correcting patients' daily dietary habits will improve food intake resulting in weight gain and improved physical functioning, role functioning, and body image \[[@b6-crt-2015-398]\]. Patients with impaired cognitive functioning should undergo a complete medical checkup and consult with a neurologist or a psychiatrist. In addition, patients should be encouraged to preserve self-esteem and maintain social activity \[[@b18-crt-2015-398]\]. These suggestions can be applied to relapse-free survivors after gastrectomy.

It is recommended that changes in postoperative QoL be used to inform patients about what to expect after surgery and to guide timely supportive postoperative interventions. Surgeons should reassure patients that QoL will mostly return to baseline about 1 year after surgery and that QoL related to upper gastrointestinal symptoms will still be lower but these symptoms will be managed individually and on a timely basis.

This study has several strengths. We enrolled consecutive patients undergoing gastrectomy by the same small group of surgeons at one institution and prospectively collected data on QoL. The inclusion of the preoperative QoL data of all patients and the postoperative assessments at fixed times enables the comparison of QoL between baseline and postoperative changes in QoL. However, premorbid QoL may be the most valid baseline measure of QoL. Preoperative QoL refers to QoL that has not yet been altered by surgery and still represents postmorbid QoL. Preoperative-based interpretations of postoperative change in QoL may not only exaggerate the persistence of decreased QoL but also conceal ongoing QoL deterioration after surgery \[[@b1-crt-2015-398]\]. Despite this limitation, we considered preoperative QoL as the baseline because acquiring data regarding premorbid QoL from patients was not feasible in clinical practice.

Conclusion
==========

Management of gastrointestinal symptoms should be specifically targeted as a part of long-term patient care after a gastrectomy. Proper nutritional care will improve food intake resulting in weight gain and improved physical functioning, role functioning, and body image. In addition, patients should be encouraged to preserve self-esteem and maintain social activity.
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###### 

Characteristics of patients

  Characteristic                                             No. of patients (%)
  ---------------------------------------------------------- ---------------------
  **Age, mean±SD (yr)**                                      54.9±10.7
  **Sex**                                                    
   Female                                                    95 (37.4)
   Male                                                      159 (62.6)
  **Stage**[^a)^](#tfn1-crt-2015-398){ref-type="table-fn"}   
   IA                                                        171 (67.3)
   IB                                                        30 (11.8)
   IIA                                                       23 (9.1)
   IIB                                                       15 (5.9)
   IIIA                                                      8 (3.1)
   IIIB                                                      5 (2.0)
   IIIC                                                      1 (0.4)
   IV                                                        1 (0.4)
  **Pathological type**                                      
   Differentiated                                            97 (38.2)
   Undifferentiated                                          157 (61.8)
  **Type of gastrectomy**                                    
   Open distal gastrectomy                                   161 (63.4)
   Open total gastrectomy                                    48 (18.9)
   Laparoscopy-assisted distal gastrectomy                   41 (16.1)
   Laparoscopy-assisted total gastrectomy                    3 (1.2)
   Robot-assisted total gastrectomy                          1 (0.4)
  **Adjuvant chemotherapy**                                  
   Yes                                                       30 (11.8)
   No                                                        224 (88.2)

The 7th edition of the American Joint Committee on Cancer Classification.

###### 

Mean scores of EORTC QLQ-C30 and QLQ-STO22 scales/items

  Variable                             Baseline    5 Years after a gastrectomy   p-value
  ------------------------------------ ----------- ----------------------------- ----------
  **Global health status/QoL**         67.7±21.4   73.5±23.5                     0.101
  **QLQ-C30 function scales**                                                    
   Physical functioning                91.4±9.7    85.6±14.3                     \< 0.001
   Role functioning                    93.2±14.3   86.7±19.8                     \< 0.001
   Emotional functioning               80.0±19.3   85.5±18.2                     0.012
   Cognitive functioning               90.8±13.5   84.2±15.8                     \< 0.001
   Social functioning                  88.2±18.0   87.4±18.8                     \> 0.999
  **QLQ-C30 symptom scales/items**                                               
   Fatigue                             19.3±18.9   24.4±19.8                     0.045
   Nausea and vomiting                 6.7±13.8    9.9±15.2                      0.177
   Pain                                8.9±15.7    8.1±13.8                      \> 0.999
   Dyspnea                             8.3±16.4    12.5±19.6                     0.128
   Insomnia                            13.3±22.5   14.2±24.3                     \> 0.999
   Appetite loss                       8.8±18.9    10.4±20.4                     \> 0.999
   Constipation                        11.2±18.8   13.1±20.2                     0.988
   Diarrhea                            11.4±19.7   21.0±23.4                     \< 0.001
   Financial difficulties              16.6±25.7   14.3±22.8                     0.993
  **QLQ-STO22 symptom scales/items**                                             
   Dysphagia                           4.6±8.9     9.3±11.1                      \< 0.001
   Pain                                13.6±15.3   13.8±15.1                     \> 0.999
   Reflux symptoms                     9.7±14.5    13.9±16.2                     0.029
   Eating restrictions                 5.3±10.2    12.4±14.8                     \< 0.001
   Anxiety                             23.9±20.6   25.7±20.0                     \> 0.999
   Dry mouth                           15.5±22.8   20.1±25.4                     0.661
   Taste                               3.3±11.6    6.2±15.2                      0.232
   Body image                          13.6±23.4   21.8±26.1                     0.003
   Hair loss                           34.7±35.3   38.2±28.3                     \> 0.999

Values are presented as mean±standard deviation. EORTC, European Organization for Research and Treatment of Cancer; QLQ, Quality of Life Questionnaire; QoL, quality of life.
